04:31 PM EDT, 05/16/2024 (MT Newswires) -- Axonics ( AXNX ) late Thursday said Australian regulators have cleared the company's Axonics F15 sacral neuromodulation device to treat adults with overactive bladders.

The implant is relatively small and thin and only takes up 10 cubic centimeters of volume. The device uses a battery expected to work inside the body for at least 15 years at typical stimulation settings and more than 20 years at lower energy settings.

Axonics ( AXNX ) began commercial activities in Australia in March 2023 and also markets a hydrogel to treat stress urinary incontinence in women.